Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
73 stopped studies mapped to Adult Acute Myeloid Leukemia and descendants · 79% state a reason
Over the 73 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03766126 | Lentivirally Redirected CD123 Autologous T Cells in AML | Phase 1 | terminated | Dec 6, 2018 | University of Pennsylvania | Administrative reasons. | Other (stated, no rule matched) |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or… | Phase 2 | terminated | May 10, 2017 | University of Southern California | Lack of funding | Funding |
| NCT02333162 | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in… | Phase 1 | suspended | Jan 7, 2015 | University of Chicago | Enrollment on hold pending amendment | Enrollment / accrual |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Mar 6, 2015 | National Cancer Institute (NCI) | Other - Adverse Events | Safety / toxicity |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not… | Phase 1 / Phase 2 | terminated | Jun 10, 2024 | Institute of Hematology & Blood Diseases Hospital, China | The number of participants in the study did not meet expectations | Other (stated, no rule matched) |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute… | Phase 1 / Phase 2 | terminated | May 25, 2018 | Sumithira Vasu | Poor acccrual | Other (stated, no rule matched) |
| NCT06200441 | Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and… | — | withdrawn | Jan 11, 2024 | Ugur Arzu Kulu | Kits were not available due to lack of sponsorship | Other (stated, no rule matched) |
| NCT04310592 | Natural Killer Cell (CYNK-001) Infusions in Adults with AML(CYNK001AML01) | Phase 1 | terminated | Mar 17, 2020 | Celularity Incorporated | Business reasons | Sponsor / business decision |
| NCT04755244 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia… | Phase 1 | terminated | Feb 16, 2021 | ALX Oncology Inc. | While intended to be a Phase 1/2 clinical study, the study never moved forward to Phase 2. | Other (stated, no rule matched) |
| NCT05601466 | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia | Phase 1 | terminated | Nov 1, 2022 | Institute of Hematology & Blood Diseases Hospital, China | It did not reach the expected results of clinical trial | Other (stated, no rule matched) |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Phase 1 | terminated | Mar 21, 2019 | Cyclacel Pharmaceuticals, Inc. | Switch to oral formulation of CYC140 (plogosertib) | Other (stated, no rule matched) |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | Phase 1 / Phase 2 | withdrawn | Sep 19, 2024 | Institute of Hematology & Blood Diseases Hospital, China | withdrawn | Other (stated, no rule matched) |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With… | Phase 1 | withdrawn | Aug 23, 2023 | Medical College of Wisconsin | Sponsor withdrew support. | Other (stated, no rule matched) |
| NCT02353143 | Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia(ARMY) | Phase 1 | terminated | Feb 2, 2015 | Menarini Group | The Sponsor accepted the iDSMB recommendation to terminate the study due to evidence of… | Safety / toxicity |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem… | Phase 1 / Phase 2 | terminated | Oct 8, 2007 | City of Hope Medical Center | Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than… | Enrollment / accrual |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Nov 4, 2020 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome… | Phase 1 / Phase 2 | terminated | Sep 6, 2019 | H Scott Boswell | Funder requested termination due to halting internal development of TAK-659 | Other (stated, no rule matched) |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | Phase 1 / Phase 2 | withdrawn | Apr 30, 2019 | Actinium Pharmaceuticals | study postponed | Other (stated, no rule matched) |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and… | Phase 2 | terminated | Jul 13, 2005 | Fred Hutchinson Cancer Center | Funding ended before target accrual was reached; participants are no longer being examined or… | Enrollment / accrual |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | Phase 1 | terminated | Aug 4, 2020 | Insel Gruppe AG, University Hospital Bern | Insufficient recruitment | Enrollment / accrual |
| NCT04425655 | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed… | Phase 2 | terminated | Jun 11, 2020 | University of California, San Diego | Original investigator for the trial has left | Investigator |
| NCT02267863 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | Phase 1 | terminated | Oct 20, 2014 | Aptose Biosciences Inc. | Drug manufacturing process and procedure review | Drug supply |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2012 | Roswell Park Cancer Institute | Sponsor wanted study rewritten | Other (stated, no rule matched) |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jul 13, 2012 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT01876953 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jun 13, 2013 | City of Hope Medical Center | Due to the budget issues, the study discontinued at Phase II. | Funding |
| NCT03951961 | Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After… | Phase 2 | terminated | May 16, 2019 | University of Jena | Insufficient Recruitment | Enrollment / accrual |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With… | Phase 1 | terminated | May 9, 2018 | University of Southern California | Study drug supply issue | Drug supply |
| NCT02105116 | AML Therapy With Irradiated Allogeneic Cells | N/A | terminated | Apr 7, 2014 | Rutgers, The State University of New Jersey | No patients were eligible to receive the experimental component of the protocol therapy. | Other (stated, no rule matched) |
| NCT04128020 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation… | Phase 1 | withdrawn | Oct 16, 2019 | Sherif Farag | Funder withdrew funding after not accruing any subjects after 1 year. | Enrollment / accrual |
| NCT02038153 | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone… | Phase 1 / Phase 2 | terminated | Jan 16, 2014 | Albert Einstein College of Medicine | Low accrual | Enrollment / accrual |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | Phase 1 | withdrawn | Aug 2, 2018 | Celyad Oncology SA | Sponsor decision | Sponsor / business decision |
| NCT02337478 | Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute… | Phase 2 | terminated | Jan 13, 2015 | Wake Forest University Health Sciences | The study was stopped early due to futility. | Efficacy / futility |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid… | Phase 2 | terminated | Dec 18, 2015 | Mayo Clinic | not stated | Not stated |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Jan 8, 2014 | Steven E. Coutre | Regulatory | Other (stated, no rule matched) |
| NCT01849276 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Phase 1 | terminated | May 8, 2013 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT02587871 | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute… | Phase 2 | withdrawn | Oct 27, 2015 | University of Southern California | PI decided not to pursue study | Other (stated, no rule matched) |
| NCT01904643 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or… | Phase 1 | terminated | Jul 22, 2013 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer,… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02472626 | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating… | Phase 1 / Phase 2 | withdrawn | Jun 16, 2015 | Wake Forest University Health Sciences | Drug Supply Issues | Drug supply |
| NCT01548911 | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | Phase 2 | withdrawn | Mar 8, 2012 | Wake Forest University Health Sciences | not stated | Not stated |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | withdrawn | Apr 18, 2013 | Stanford University | not stated | Not stated |
| NCT02635074 | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Dec 18, 2015 | Steven E. Coutre | safety | Safety / toxicity |
| NCT02723435 | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | Phase 2 | withdrawn | Mar 30, 2016 | Stanford University | Logistical and administrative issues | Other (stated, no rule matched) |
| NCT01907815 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | Phase 2 | terminated | Jul 25, 2013 | National Cancer Institute (NCI) | Lack of efficacy. | Efficacy / futility |
| NCT01801046 | Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia | Phase 1 | terminated | Feb 28, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | Phase 2 | terminated | Mar 27, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 10, 2026source: clinicaltrials